MicroRNAs are important regulators of drug resistance in colorectal cancer

Zhang, Yang; Wang, Jing

doi:10.1515/hsz-2016-0308

Cited by 64 publications

(45 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CTC lines expressed high levels of drug metabolism genes and were resistant to conventional therapies. (Grillet et al, 2017) subtypes of CRC attain the ability to disrupt drug transport, dysregulate cellular processes, alter drug sensitivity (via genetic or epigenetic modifications) and targets of therapy, that subsequently limit the efficacy of existing anti-cancer therapies (Holohan et al, 2013;Panczyk, 2014;Hu et al, 2016;Zhang and Wang, 2017;Hon et al, 2018;Abu et al, 2019). Since there are hints that metastasis and chemoresistance can be interconnected (Zheng, 2017;Durinikova et al, 2018), the previous can be prevented if chemoresistant subtypes are identified early for optimal or more aggressive treatment.…”

Section: Possible Solution To Crc Chemoresistancementioning

confidence: 99%

Single Cell Transcriptome in Colorectal Cancer—Current Updates on Its Application in Metastasis, Chemoresistance and the Roles of Circulating Tumor Cells

et al. 2020

View full text Add to dashboard Cite

Colorectal cancer (CRC) is among the most common cancer worldwide, a challenge for research, and a model for studying the molecular mechanisms involved in its development. Previously, bulk transcriptomics analyses were utilized to classify CRC based on its distinct molecular and clinicopathological features for prognosis and diagnosis of patients. The introduction of single-cell transcriptomics completely turned the table by enabling the examination of the expression levels of individual cancer cell within a single tumor. In this review, we highlighted the importance of these single-cell transcriptomics analyses as well as suggesting circulating tumor cells (CTCs) as the main focus of single-cell RNA sequencing. Characterization of these cells might reveal the intratumoral heterogeneity present in CRC while providing critical insights into cancer metastasis. To summarize, we believed the analysis of gene expression patterns of CTC from CRC at single-cell resolution holds the potential to provide key information for identification of prognostic and diagnostic markers as well as the development of precise and personalized cancer treatment.

show abstract

Section: Possible Solution To Crc Chemoresistancementioning

confidence: 99%

Single Cell Transcriptome in Colorectal Cancer—Current Updates on Its Application in Metastasis, Chemoresistance and the Roles of Circulating Tumor Cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In recent years, microRNAs (miRNAs) have been proposed as biomarkers of CDR [10][11][12][13]. These are small noncoding RNAs that regulate gene expression by post-transcriptionally targeting the 3 -UTR region of mRNA.…”

Section: Introductionmentioning

confidence: 99%

ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance

Gomes

Honrado

Armada

et al. 2020

IJMS

View full text Add to dashboard Cite

Cancer drug resistance (CDR) is a major problem in therapeutic failure. Over 90% of patients with metastatic cancer present CDR. Several mechanisms underlie CDR, including the increased expression of efflux ABC transporters and epigenetic phenomena. Nevertheless, a topic that is not usually addressed is the mechanism underlying the loss of CDR once the challenge to these cells is withdrawn. A KCR cell line (doxorubicin-resistant, expressing ABCB1) was used to induce loss of resistance by withdrawing doxorubicin in culture medium. ABCB1 activity was analysed by fluorescence microscopy and flow cytometry through substrate (DiOC2) retention assays. The expression of 1008 microRNAs was assessed before and after doxorubicin withdrawal. After 16 weeks of doxorubicin withdrawal, a decrease of ABCB1 activity and expression occurred. Moreover, we determined a signature of 23 microRNAs, 13 underexpressed and 10 overexpressed, as a tool to assess loss of resistance. Through pathway enrichment analysis, "Pathways in cancer", "Proteoglycans in cancer" and "ECM-receptor interaction" were identified as relevant in the loss of CDR. Taken together, the data reinforce the assumption that ABCB1 plays a major role in the kinetics of CDR, and their levels of expression are in the dependence of the circuitry of cell miRNAs.

show abstract

“…Colorectal cancer and many other cancers are often the result of molecular alterations that lead to the enhanced function of oncogenes or loss of function of tumour‐suppressor genes . Suppression of the activator protein 1 (AP‐1), regulated by IFN (SARI), was demonstrated to be down‐regulated in CRC, and SARI expression was inversely correlated with poor clinical outcomes in patients with CRC .…”

Section: Discussionmentioning

confidence: 99%

SEZ6L2 knockdown impairs tumour growth by promoting caspase‐dependent apoptosis in colorectal cancer

Zhao

Lan

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

| 4223 wileyonlinelibrary.com/journal/jcmm | INTRODUC TI ONColorectal cancer (CRC) has been a common malignancy and leading cause of cancer mortality in the developed and developing countries, in recent years. 1 Epidemiological data in recent years suggest that the 5-year prevalence of CRC has reached 74.6 and 58.3 per 100 000 men and women, respectively. 2 According to the data, approximately 41% of all CRCs occur in the proximal colon, while 22% occur in the distal colon and 28% in the rectum. 2 With the advancements in understanding the pathogenesis, CRC is typically seen as a series of mutations and epigenetic changes that accumulate slowly, which may lead to a loss of function in tumour-suppressor genes and an increase in oncogenes. [3][4][5] Thus, understanding the function and mechanism of hub genes during CRC development AbstractSeizure-related 6 homolog (mouse)-like 2 (SEZ6L2) was shown to be involved in transcription of a type 1 transmembrane protein for regulating cell fate. Until now, the expression and function of SEZ6L2 in various cancers, including colorectal cancer (CRC), were unclear. In the present study, we determined the expression of SEZ6L2 in a tissue microarray from patients with CRC and then, analysed the correlation between SEZ6L2 expression and the prognosis of the patients. Furthermore, the potential function of SEZ6L2 in CRC was determined using cell counting kit, colony formation assay and xenograft model in vitro and in vivo. Flow cytometry, Western

show abstract

MicroRNAs are important regulators of drug resistance in colorectal cancer

Cited by 64 publications

References 75 publications

Single Cell Transcriptome in Colorectal Cancer—Current Updates on Its Application in Metastasis, Chemoresistance and the Roles of Circulating Tumor Cells

Single Cell Transcriptome in Colorectal Cancer—Current Updates on Its Application in Metastasis, Chemoresistance and the Roles of Circulating Tumor Cells

ABC Efflux Transporters and the Circuitry of miRNAs: Kinetics of Expression in Cancer Drug Resistance

SEZ6L2 knockdown impairs tumour growth by promoting caspase‐dependent apoptosis in colorectal cancer

Contact Info

Product

Resources

About